urelumab

Urelumab is a fully human IgG4 monoclonal antibody that acts as an agonist of CD137 (also known as 4‑1BB or TNFRSF9), a co-stimulatory receptor expressed on activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. By binding to the extracellular domain of CD137, urelumab stimulates the proliferation and survival of activated CD8+ T cells and NK cells, enhances cytokine production (such as IL‑2 and IFN‑γ), increases cytotoxic activity against tumor cells, and promotes long-term memory T cell formation. These effects collectively boost anti-tumor immunity. Urelumab was developed using Medarex's UltiMAb technology by Bristol Myers Squibb for use in cancer immunotherapy. Its clinical development has been limited by dose-dependent liver toxicity; the maximum tolerated dose is 0.1 mg/kg. Urelumab has been studied in various cancers including solid tumors, non-Hodgkin’s lymphoma, melanoma, leukemia, multiple myeloma, colorectal cancer, glioblastoma, head and neck cancer, and non-small cell lung cancer[1][3][4][5][6].

Other names

anti-CD137 monoclonal antibodyanti-CD-137 monoclonal antibodyanti-CD 137 monoclonal antibodyanti-4-1BB monoclonal antibodyanti4-1BB monoclonal antibodyanti 4-1BB monoclonal antibody